论文部分内容阅读
卡维地洛(carvedilol)是一种新型的非选择性肾上腺素能受体阻滞剂,具有β受体和α受体双重阻滞、调节细胞因子、抗氧化、抗心脏重构和抗心律失常等多方面的作用,无内在拟交感活性,避免了反射性交感神经兴奋所引起的周围血管收缩及外周阻力增加,通过减轻心肌炎症,延缓并逆转心室重构,改善血流动力学,改善预后。目前关于卡维地洛治疗或干预儿童病毒性心肌炎、扩张型心肌病、心律失常已逐渐受到重视。现对卡维地洛治疗儿童心血管系统疾病研究进展做一综述。
Carvedilol is a new nonselective adrenergic receptor blocker with dual blockade of beta and alpha receptors, modulation of cytokines, antioxidation, anti-cardiac remodeling, and antiarrhythmics Disorders and other aspects of the role, there is no intrinsic sympathetic activity, to avoid reflex sympathetic excitement caused by peripheral vasoconstriction and increased peripheral resistance, by reducing myocardial inflammation, delay and reverse ventricular remodeling, improve hemodynamics, improve Prognosis. Currently on the treatment of carvedilol or intervention in children with viral myocarditis, dilated cardiomyopathy, arrhythmia has gradually been taken seriously. The progress of carvedilol treatment of children with cardiovascular diseases are reviewed.